Symlin And Byetta Excluded From American Diabetes Association Guideline
Executive Summary
Amylin's Symlin and Byetta are among several products excluded from a recommended treatment guideline for type 2 diabetes from the American Diabetes Association
You may also be interested in...
Mid-Cap Biotechs Rise In ’06; Small Firms Face “Burden” Of New Products
Disappointing product launches by CV Therapeutics and NitroMed underscore the challenges that small manufacturers face in trying to successfully bring new products to market
Mid-Cap Biotechs Rise In ’06; Small Firms Face “Burden” Of New Products
Disappointing product launches by CV Therapeutics and NitroMed underscore the challenges that small manufacturers face in trying to successfully bring new products to market
GSK Pushing For ADOPTion Of Avandia For First-Line Type 2 Diabetes Therapy
GlaxoSmithKline plans to use the results of its ADOPT study to establish its thiazolidinedioneAvandia as the standard first-line treatment for type 2 diabetes